Robert C. Goeltz, II is the Chief Financial Officer at Arcus Biosciences, Inc., a biotechnology company focused on developing innovative cancer immunotherapies. With a robust background in finance and strategic planning, Goeltz brings a wealth of experience to his role. Prior to joining Arcus Biosciences, he served as the CFO at Calithera Biosciences, where he played a pivotal role in guiding the company through its initial public offering and subsequent growth phases. His strategic financial leadership was instrumental in securing funding and driving the company's research and development initiatives. Before his tenure at Calithera Biosciences, Goeltz held significant positions at other notable biotech firms, including Affymax, Inc., and Abgenix, Inc. At Affymax, he served as Vice President of Finance and Corporate Controller, overseeing financial operations and contributing to the company's strategic direction. His earlier career at Abgenix saw him in various financial roles that honed his skills in corporate finance and investor relations. Goeltz's academic credentials include a Bachelor of Science in Business Administration from the University of California, Berkeley, and he is a Certified Public Accountant. As CFO at Arcus Biosciences, Goeltz is responsible for overseeing all financial aspects of the company, including financial planning, budgeting, and investor relations. His leadership has been crucial in navigating the complex financial landscape of the biotech industry, ensuring that Arcus Biosciences remains well-positioned to advance its mission of transforming cancer treatment. Under his guidance, the company has successfully raised capital and formed strategic partnerships, which have been vital for the development and commercialization of its innovative therapies. Goeltz's strategic vision and financial acumen continue to drive Arcus Biosciences towards achieving its goals in the fight against cancer.